Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
26.06
-0.98 (-3.62%)
Mar 9, 2026, 12:13 PM EDT - Market open
Surrozen Employees
As of December 31, 2024, Surrozen had 41 total employees, including 40 full-time and 1 part-time employees. The number of employees decreased by 1 or -2.38% compared to the previous year.
Employees
41
Change (1Y)
-1
Growth (1Y)
-2.38%
Revenue / Employee
$87,902
Profits / Employee
-$2,119,659
Market Cap
242.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41 | -1 | -2.38% |
| Dec 31, 2023 | 42 | -32 | -43.24% |
| Dec 31, 2022 | 74 | -9 | -10.84% |
| Dec 31, 2021 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Abeona Therapeutics | 136 |
| Prelude Therapeutics | 131 |
| OmniAb | 114 |
| Orchestra BioMed Holdings | 70 |
| Fennec Pharmaceuticals | 32 |
| Ovid Therapeutics | 23 |
| Inhibikase Therapeutics | 16 |
SRZN News
- 11 days ago - Surrozen to Present at Upcoming Healthcare Investor Conference - GlobeNewsWire
- 13 days ago - Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 4 months ago - Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 months ago - Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - GlobeNewsWire
- 10 months ago - Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire